Adeno-associated virus (AAV) gene therapies have fundamentally altered the treatment landscape for rare and genetic diseases, delivering significant outcomes that validate the potential of genetic medicine. However, as the field matures, the primary challenge for developers has shifted from proving clinical efficacy to ensuring these therapies can be reliably developed, manufactured, scaled, and delivered in a commercially sustainable manner.
Developers currently face a complex environment marked by rising demand, manufacturing capacity constraints, global supply chain considerations, and heightened expectations for commercial readiness. Traditional methods that sufficed during early clinical stages are often inadequate as programs advance toward registration, launch, and long-term supply. Consequently, the industry is increasingly prioritizing platform technologies, integrated development strategies, resilient supply chains, and manufacturing innovations designed to accelerate timelines while enhancing scalability and consistency.
A new eBook published by GEN - Genetic Engineering and Biotechnology News compiles perspectives from across the AAV development and manufacturing continuum. The resource explores how early commercial planning can prevent costly delays and details how standardized platform approaches and off-the-shelf plasmids can streamline the development process. Furthermore, it examines how next-generation innovations are addressing long-standing manufacturing bottlenecks.
The publication also highlights the growing importance of supply chain orchestration and case management in ensuring therapies reach patients safely, efficiently, and on schedule. As more AAV-based therapies progress through clinical development toward commercialization, organizations that successfully integrate manufacturing strategy, supply chain planning, and technological innovation will be best positioned to deliver treatments at scale. The insights provided offer a practical roadmap for developers aiming to accelerate development, optimize manufacturing performance, strengthen supply resilience, and ultimately improve patient access to transformative medicines.